tiprankstipranks
Atara Biotherapeutics Announces CEO Transition and New Leadership Compensation
Company Announcements

Atara Biotherapeutics Announces CEO Transition and New Leadership Compensation

Pick the best stocks and maximize your portfolio:

Atara Biotherapeutics (ATRA) has provided an announcement.

Pascal Touchon is set to resign as President and CEO of his company, transitioning to Chairman of the Board after September 9, 2024. He will consult for the company for up to 18 months post-separation. AnhCo Nguyen, with a background in research and development at Fate Therapeutics and Pfizer, will succeed Touchon. Nguyen’s compensation includes a $650,000 base salary, potential bonuses, and a sizeable stock unit award, reflecting the board’s confidence in his ability to lead the company into its next phase.

For an in-depth examination of ATRA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAtara Biotherapeutics initiated with a Buy at Rodman & Renshaw
TipRanks Auto-Generated NewsdeskAtara Biotherapeutics Reports Q3 2024 Financial Progress
TheFlyAtara Biotherapeutics price target raised to $21 from $13 at Canaccord
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App